HHV Announces Investment in Luminostics, Inc

HHV has announced its investment in Luminostics, Inc. David Franklin, Managing Director of HHV states, “We are very excited to bring Luminostics’ rapid biosensing platform into our portfolio. They are developing a very elegant at-home STD screening test as their first product.”

Luminostics is a startup based on smartphone-based rapid test technology for diseases and other medical conditions developed at the University of Houston. Luminostics’ vision is to empower consumers by enabling instant, on-demand access to health information at a molecular level. Luminostics’ first product is a rapid at-home screening test for Chlamydia. It uses a smartphone’s camera to interface with a nanotechnology-enabled disposal test cartridge and accurately read the test results. For more on the technology please see:

Full Press Release